Lack of association of the CIITA -168A→G promoter SNP with myasthenia gravis and its role in autoimmunity

BMC Med Genet. 2010 Oct 13:11:147. doi: 10.1186/1471-2350-11-147.

Abstract

Background: The major histocompatibility complex class II transactivator (CIITA) regulates MHC class II gene expression. A promoter SNP -168A→G (rs3087456) has previously been shown to be associated with susceptibility to several immune mediated disorders, including rheumatoid arthritis (RA), multiple sclerosis (MS) and myocardial infarction (MI). Myasthenia gravis (MG) is an autoimmune disorder which has previously been shown to be associated with polymorphisms of several autoimmune predisposing genes, including IL-1, PTPN22, TNF-α and the MHC. In order to determine if allelic variants of rs3087456 increase predisposition to MG, we analyzed this SNP in our Swedish cohort of 446 MG patients and 1866 controls.

Results: No significant association of the SNP with MG was detected, neither in the patient group as a whole, nor in any clinical subgroup. The vast majority of previous replication studies have also not found an association of the SNP with autoimmune disorders.

Conclusions: We thus conclude that previous findings with regard to the role of the CIITA -168A→G SNP in autoimmunity may have to be reconsidered.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Autoimmunity / genetics*
  • Case-Control Studies
  • Cohort Studies
  • Humans
  • Infant, Newborn
  • Middle Aged
  • Myasthenia Gravis / epidemiology
  • Myasthenia Gravis / genetics*
  • Myasthenia Gravis / immunology*
  • Nuclear Proteins / genetics*
  • Polymorphism, Single Nucleotide / genetics*
  • Prognosis
  • Promoter Regions, Genetic / genetics*
  • Sweden / epidemiology
  • Trans-Activators / genetics*

Substances

  • MHC class II transactivator protein
  • Nuclear Proteins
  • Trans-Activators